Receptor.AI is a TechBio drug discovery company that combines a multi-platform AI ecosystem with a modality-agnostic decision engine to define the right therapeutic strategy and design the right molecule to address complex target biology. Our ecosystem integrates small molecules, peptides, and induced-proximity therapeutics, enabling objective comparison and selection of drug discovery approaches. This allows us to design molecules that align with strategic program direction and increase the probability of clinical success. We partner with pharma and biotech organizations to advance high-confidence programs toward the clinic, with capabilities validated across 40+ discovery programs and guided by experts behind FDA-approved and clinical-stage medicines.
| Website | http://www.receptor.ai |
| Employees | 44 (31 on RocketReach) |
| Founded | 2021 |
| Address | 100 Cambridgepark Dr, Cambridge, Massachusetts 02140, US |
| Industry | Biotechnology Research |
| Keywords | Ai Drug Discovery, Pharmaceutical Ai, Biotechnology Ai, Computational Drug Design, Ai In Pharma, In Silico Drug Discovery, Drug Discovery Technology, Accelerated Drug Development, Molecular Design, Precision Medicine |
| Competitors | OpenAI, IBM, NVIDIA, Microsoft, Amazon, C3 AI, Salesforce, DataRobot, H2O.ai, Zoho +43 more (view full list) |
Looking for a particular RECEPTOR.AI employee's phone or email?
Alan Nafiev is the CEO and Founder of RECEPTOR.AI.
31 people are employed at RECEPTOR.AI.
RECEPTOR.AI is based in Cambridge, Massachusetts.